What question did this study set out to answer?

To review the shift from conventional ex vivo CAR T cell manufacturing to direct in vivo engineering using engineered vectors and nanoparticles.

April 12, 2024Trends in Pharmacological SciencesOpen Access

Direct in vivo CAR T cell engineering

View Full Paper

Ask AI

Bookmark

To review the shift from conventional ex vivo CAR T cell manufacturing to direct in vivo engineering using engineered vectors and nanoparticles.
Evaluated the standard ex vivo manufacturing process as a baseline framework.
Synthesized preclinical data on direct infusion platforms utilizing nanoparticle-formulated nucleic acids and engineered viral vectors.
Direct in vivo engineering platforms successfully generate functional CAR T cells with therapeutic potency in preclinical models without ex vivo processing.
Key clinical translation bottlenecks persist, primarily involving target cell delivery specificity, duration of therapeutic efficacy, and systemic safety profiles.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Narrative review reveals advances in direct in vivo CAR T cell engineering in preclinical models, suggesting viable alternatives to complex ex vivo manufacturing.

Cite This Study

Short et al. (2024) studied this question.

synapsesocial.com/papers/69d9a63ba1d151c65f684bc7 https://doi.org/10.1016/j.tips.2024.03.004

View Full Paper

Ask AI

Bookmark

Implication

Narrative review reveals advances in direct in vivo CAR T cell engineering in preclinical models, suggesting viable alternatives to complex ex vivo manufacturing.

Direct in vivo CAR T cell engineering

Key Points

Discussion

Implication

Cite This Study

Direct in vivo CAR T cell engineering

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider